LEADER 00968nam a2200265 i 4500 001 991001164559707536 008 050721s2002 enka b 001 0 eng 020 $a0521773091 035 $ab13330202-39ule_inst 040 $aDip.to Filologia Ling. e Lett. 082 00$a413/.028$221 100 1 $aWray, Alison$0317313 245 10$aFormulaic language and the lexicon /$cAlison Wray 260 $aCambridge ;$aNew York :$bCambridge University Press,$c2002 300 $axi, 332 p. :$bill. ;$c24 cm 650 4$aAnalisi linguistica 650 4$aAcquisizione linguistica 650 4$a Lessicologia$xMetodologia 650 4$aAfasia 907 $a.b13330202$b21-09-06$c21-07-05 912 $a991001164559707536 945 $aLE008 FL.M. (L.G.) M 89$c1$g1$i2008000109417$lle008$op$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i1411088x$z21-07-05 996 $aFormulaic language and the lexicon$9614648 997 $aUNISALENTO 998 $ale008$b21-07-05$cm$da $e-$feng$genk$h0$i0 LEADER 03832oam 2200709I 450 001 9910959037503321 005 20240401185141.0 010 $a1-04-021213-1 010 $a0-429-16933-7 010 $a1-4665-9387-3 024 7 $a10.1201/b16749 035 $a(CKB)3710000000099004 035 $a(EBL)1408064 035 $a(SSID)ssj0001181236 035 $a(PQKBManifestationID)11639740 035 $a(PQKBTitleCode)TC0001181236 035 $a(PQKBWorkID)11143189 035 $a(PQKB)11074665 035 $a(OCoLC)880460508 035 $a(MiAaPQ)EBC1408064 035 $a(OCoLC)876288586 035 $a(EXLCZ)993710000000099004 100 $a20180331h20142014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aClinical and statistical considerations in personalized medicine /$fedited by Claudio Carini, Pfizer, Cambridge, Massachusetts, USA, Sandeep M. Menon, Pfizer, Cambridge, Massachusetts, USA, Mark Chang, AMAG Pharmaceuticals, Incorporated Waltham, Massach 205 $a1st ed. 210 1$aBoca Raton :$cCRC Press,$d[2014] 210 4$dİ2014 215 $a1 online resource (368 p.) 225 1 $aChapman and Hall/CRC Biostatistics Series 300 $aDescription based upon print version of record. 311 08$a1-306-86777-0 311 08$a1-4665-9386-5 320 $aIncludes bibliographical references. 327 $aFront Cover; Contents; Preface; Editors; Contributors; Chapter 1: Biomarkers for Drug Development: The Time Is Now!; Chapter 2: RNAi Screens: Triumphs and Tribulations; Chapter 3: Current Advances in Epigenetics; Chapter 4: Biomarkers and Precision Medicine: The Case of Rare Diseases; Chapter 5: Biomarker-Informed Adaptive Design; Chapter 6: Fitting the Dose: Adaptive Staggered Dose Design; Chapter 7: Evidence-Based Adaptive Statistical Decision and Design Strategies for; Chapter 8: Biomarker Identification in Clinical Trials; Chapter 9: Multiplicity in Pharmacogenomics 327 $aChapter 10: Patient-Reported Outcomes in Personalized MedicineChapter 11: Regulatory Issues in Use of Biomarkers in Drug Development; Back Cover 330 $aPersonalized medicine has the potential to change the way we think about, identify, and manage health problems. In the pharmaceutical industry, it is already having an exciting impact on both clinical research and patient care. This impact will continue to grow as our understanding and technologies improve. With contributions from well-known industry leaders in clinical development, this book covers the practical aspects of personalized medicine, focusing on issues that have direct application in the industry. Topics include designs for targeted therapy, adaptive designs, evidence-based adaptive statistical decisions, and design strategies for maximizing the efficiency of clinical oncology--$cProvided by publisher. 410 0$aChapman & Hall/CRC biostatistics series (Unnumbered) 606 $aPharmacogenetics$xMathematical models 606 $aPharmacogenetics$xStatistical methods 606 $aPharmacogenomics$xMathematical models 606 $aPharmacogenomics$xStatistical methods 615 0$aPharmacogenetics$xMathematical models. 615 0$aPharmacogenetics$xStatistical methods. 615 0$aPharmacogenomics$xMathematical models. 615 0$aPharmacogenomics$xStatistical methods. 676 $a615.7072/7 676 $a615.70727 686 $aMAT029000$aMED045000$aMED071000$2bisacsh 702 $aCarini$b Claudio 702 $aMenon$b Sandeep M. 702 $aChang$b Mark 801 0$bFlBoTFG 801 1$bFlBoTFG 906 $aBOOK 912 $a9910959037503321 996 $aClinical and statistical considerations in personalized medicine$94398615 997 $aUNINA